Cover Image

No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group

Chronic myeloid leukaemia, imatinib, hydroxyurea/imatinib, outcome, phase I, phase II

Saved in:
Bibliographic Details
Main Authors: Lange, Thoralf (Author) , Niederwieser, Christian (Author) , Gil, Arthur (Author) , Krahl, Rainer (Author) , Grünhagen, Ulrich von (Author) , Al-Ali, Haifa Kathrin (Author) , Jentsch-Ullrich, Kathleen (Author) , Spohn, Claudia (Author) , Lakner, Volker (Author) , Assmann, Michael (Author) , Junghanss, Christian (Author) , Cross, Michael (Author) , Hehlmann, Rüdiger (Author) , Deininger, Michael (Author) , Pfirrmann, Markus (Author) , Niederwieser, Dietger (Author)
Format: Article (Journal)
Language:English
Published: 2020
In: Leukemia and lymphoma
Year: 2020, Volume: 61, Issue: 12, Pages: 2821-2830
ISSN:1029-2403
DOI:10.1080/10428194.2020.1786556
Online Access:lizenzpflichtig
Get full text
Author Notes:Thoralf Lange, Christian Niederwieser, Arthur Gil, Rainer Krahl, Ulrich von Grünhagen, Haifa Kathrin Al-Ali, Kathleen Jentsch-Ullrich, Claudia Spohn, Volker Lakner, Michael Assmann, Christian Junghanss, Michael Cross, Rüdiger Hehlmann, Michael Deininger, Markus Pfirrmann, Dietger Niederwieser
Description
Summary:Chronic myeloid leukaemia, imatinib, hydroxyurea/imatinib, outcome, phase I, phase II
Physical Description:Online Resource
ISSN:1029-2403
DOI:10.1080/10428194.2020.1786556

Similar Items